Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pain 2Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Peripheral Nervous System Diseases 1Multiple Myeloma 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Head and Neck Neoplasms 1Esophagitis 1Breast Neoplasms 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Glutamine × Clear all
NCT01783522 2019-10-22

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Case Comprehensive Cancer Center

Phase 2 Terminated
9 enrolled 10 charts
Plasma cell

Multiple Myeloma, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡